Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 2
Submit an article Journal homepage
702
Views
9
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML)

Melita Kenealya Department of Haematology, Cabrini Health, Melbourne, Australia;b Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia;c Melbourne University, Melbourne, AustraliaCorrespondence[email protected]
,
Nigel Pattond Royal Adelaide Hospital, Adelaide, Australia
,
Robin Filshiee St Vincent’s Hospital Melbourne, Australia
,
Andrew Nicolf Greenslopes Private Hospital, Brisbane, Australia
,
Shir-Jing Hog St George Hospital, Sydney, Australia
,
Mark Hertzbergh Department of Haematology, Prince of Wales Hospital and University of New South Wales, Sydney, Australia
,
Tony Millsi Princess Alexandra Hospital, Brisbane, Australia
,
Ian Prosserj Canberra Hospital, Canberra, Australia
,
Emma Linkb Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia
,
Linda Cowanb Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia
,
Diana Zanninok Australasian Leukaemia and Lymphoma Group, Melbourne, Australia
&
John F. Seymourb Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia;c Melbourne University, Melbourne, Australia
 show all
Pages 298-307 | Received 29 Jan 2016, Accepted 10 May 2016, Published online: 07 Jun 2016

Citations (9)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Zoe K. McQuilten, Ljoudmila Busija, John F. Seymour, Simon Stanworth, Erica M. Wood, Melita Kenealy & Robert Weinkove. (2022) Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia. Leukemia & Lymphoma 63:3, pages 676-683.
Read now

Articles from other publishers (8)

Hao Guo, Jingyi Yang, Haoran Wang, Xingchen Liu, Yanyan Liu & Keshu Zhou. (2022) Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms. Frontiers in Immunology 13.
Crossref
Lynette Chee, David Ritchie, Mandy Ludford‐Menting, Jane Ripley, Jessica Chung, Daniel Park, Sam Norton, Melita Kenealy & Rachel Koldej. (2022) Dysregulation of immune cell and cytokine signalling correlates with clinical outcomes in myelodysplastic syndrome (MDS). European Journal of Haematology 108:4, pages 342-353.
Crossref
Esther N. Oliva, Uwe Platzbecker, Pierre Fenaux, Guillermo Garcia-Manero, Thomas W. LeBlanc, Bhumika J. Patel, Anne Sophie Kubasch & Mikkael A. Sekeres. (2021) Targeting health-related quality of life in patients with myelodysplastic syndromes – Current knowledge and lessons to be learned. Blood Reviews 50, pages 100851.
Crossref
Antonio Piccolomo, Claudia Pia Schifone, Vanda Strafella, Giorgina Specchia, Pellegrino Musto & Francesco Albano. (2020) Immunomodulatory Drugs in Acute Myeloid Leukemia Treatment. Cancers 12:9, pages 2528.
Crossref
Claudio Fozza. (2019) Retuning the immune system in myelodysplastic syndromes: from immunomodulatory approaches to vaccination strategies and non myeloablative hemopoietic cell transplant. Critical Reviews in Oncology/Hematology 133, pages 112-119.
Crossref
Björn Tampe & Michael Zeisberg. (2018) Chromatin dynamics at the core of kidney fibrosis. Matrix Biology 68-69, pages 194-229.
Crossref
Ronan T. Swords, Steven CoutreMichael B. MarisJoshua F. Zeidner, James M. ForanJose Cruz, Harry P. ErbaJesus G. BerdejaWayne Tam, Saran Vardhanabhuti, Iwona Pawlikowska-Dobler, Hélène M. Faessel, Ajeeta B. Dash, Farhad Sedarati, Bruce J. Dezube, Douglas V. Faller & Michael R. Savona. (2018) Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. Blood 131:13, pages 1415-1424.
Crossref
Vibeke Andresen & Bjørn T. Gjertsen. (2017) Drug Repurposing for the Treatment of Acute Myeloid Leukemia. Frontiers in Medicine 4.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.